An Exploratory Study of PQ Grass 27600 SU

Summary

PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.

Timeline

Start

2020-10-19

Primary completion

2021-08-18

Completion

2021-10-28

Outcome

Met primary endpoint

registry analysis (superiority test); PQ Grass Conventional Dosing Regimen vs Placebo (Containing MCT); p = 0.0325; Median Difference (Final Values) -33.1 (80% CI -48.8 to -17.4) NCT04687059 ↗

registry analysis (superiority test); PQ Grass Extended Dosing Regimen vs Placebo (Containing MCT); p = 0.0112; Mean Difference (Final Values) -39.5 (80% CI -54.7 to -24.4) NCT04687059 ↗

release “Primary endpoint was met with a highly statistically significant dose-response relationship” allergytherapeutics.com ↗

Publications

• Layhadi JA, Starchenka S, De Kam PJ, Palmer E, Wu LYD, Keane ST, Fulton WT, Hikmawati P, Meng X, Filipaviciute P, Cutrina Pons A, Oluwayi K, Lis K, Armfield O, Skinner MA, Heath MD, Hewings SJ, Kramer MF, Shamji MH. Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. 2026 Jan;81(1):232-247. doi: 10.1111/all.16640. Epub 2025 Jul 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PQ Grass	Unknown	27600 unknown	Subcutaneous

Indications